Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 28%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. possesses a strong position in the biopharmaceutical market, particularly with its leading drug cabozantinib, which has demonstrated long-term efficacy in renal cell carcinoma (RCC) and expanded its indications in neuroendocrine tumors (NETs) following supportive trial data. Recent developments, including zanzalintinib's statistically significant improvement in overall survival in metastatic colorectal cancer (mCRC), suggest robust growth potential beyond cabozantinib. Overall, the positive trajectory of zanzalintinib, paired with ongoing successful outcomes for cabozantinib, informs a favorable outlook for Exelixis's stock performance.

Bears say

Exelixis Inc. faces a substantial revenue decline risk, with projections indicating an 80% drop in revenues by 2032 due to anticipated generic competition, exceeding market expectations of a 68% reduction. The company is exposed to various competitive risks, including market share erosion for its lead product, cabozantinib, and potential setbacks in its developmental pipeline, notably zanzalintinib. Additionally, failures or delays in obtaining regulatory approvals for their treatments could further jeopardize the company’s financial stability and share price.

Exelixis (EXEL) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 28% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 18 analysts, Exelixis (EXEL) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.